The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE webcast:
David Gerber, MD, discloses that he is on advisory boards (compensated) of Guardant Health, advisory boards (not compensated) of Boehringer-Ingelheim, BMS, Celgene, Genentech, Peregrine, Synta, and has received
research funding from ArQule, Astra-Zeneca, Boehringer-Ingelheim, BerGenBio, ImClone, ImmunoGen, Peregrine.
Don L. Gibbons, MD, PhD, discloses that he is on the advisory board of Janssen R&D and AstraZeneca, received research funding from Janssen R&D and AstraZeneca
Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.